Business Context and Reporting Period
This Form 6-K filing by Nanobiotix S.A. covers the period ending April 14, 2025. The report serves as a notification of transactions by Persons Discharging Managerial Responsibilities (PDMR) and closely associated persons, filed in compliance with the EU Market Abuse Regulation (MAR).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider transactions and does not contain financial performance data.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document solely discloses the occurrence of PDMR transactions as required by law.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of unusual items. It is a procedural report regarding compliance with the EU Market Abuse Regulation.
Key Facts for Investors
- The filing discloses transactions by company insiders (PDMR) and their associates.
- Details of the specific transactions are located in Exhibit 99.1, which is a translation of the original French filing.
- This report does not include financial statements or operational updates.
- The report was signed by Bart Van Rhijn, Chief Financial and Business Officer.